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ABSTRACT 
 
The purpose of the present study was to evaluate taste by a human sensory test and the physicochemical 
properties of loperamide hydrochloride preparations for children (Preparations A, B, and C).  Evaluation of 
bitterness revealed significantly differences between preparation C and preparation A or B.  In contrast, the 
results of solubility and palatability with a human sensory test revealed differences between preparation A and 
preparation C. Measurement of sugar content revealed that the preparations all had equivalent sugar content. 
Measurement of particle size distribution and scanning electron microscopy revealed differences in the particle 
size and particle surface morphology for each preparation. A dissolution test revealed that Preparation Chad a 
briefer period prior to dissolution than the other preparations. The taste and palatability of a preparation were 
presumably the result of differences in the rate of dissolution of the principal agent, types of additives, and the 
process by which a preparation is manufactured. In other words, the characteristics of each preparation were 
revealed by evaluation of their physical properties and human sensory test 
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INTRODUCTION 
  
When patients take a pharmaceutical, they tend to 
dislike taking it if the pharmaceutical is bitter or 
unpalatable
1, 2
. Difficulty taking a pharmaceutical 
leads to less compliance, which can in turn reduce 
its efficacy and result in a worse quality of life. The 
dissolution of preparations such as fine granules, 
dry syrups, and orally disintegrating tablets in the 
mouth can be anticipated based on the 
preparation‟s properties, and patients are acutely 
aware of a preparation‟s taste and palatability. 
Most pharmaceuticals are taken orally, and the 
good taste and easy palatability or bad taste and 
poor palatability of oral preparations greatly affect 
patient compliance. Aspects of the taste and 
palatability of a preparation, such as its bitterness, 
can be improved by masking bitterness through 
techniques such as coatings and inclusion of certain 
additives in the preparation
3-4
.  
 
As one of its efforts to reduce medical expenses, 
the Japanese Government recommends that 
medical facilities use generic pharmaceuticals 
(generics). An important task for medical personnel 
is to select generics that are safe for patients, 
efficacious, and highly palatable. Generics contain 
the same ingredients as brand-name 
pharmaceuticals (brand-name drugs) but they 
contain different preservatives, coloring agents, and 
excipients, so physicians and pharmacists often 
question their quality
5
. Generics are cheaper than 
brand-name drugs and have the same quality. 
However, many medical experts feel that there is a 
lack of clinical information on the clinical efficacy 
and safety of these drugs and inadequate 
information on the properties of 
preparations
6
.Thus, this clinical information and 
information on the properties of preparations are 
crucial to determining whether to dispense a brand-
name drug or a generic. However, assessment of 
the taste and palatability of a preparation is 
difficult, and a comprehensive evaluation of a 
preparation, i.e. whether it tastes good or bad and 
whether it is palatable or not, often depends on 
human sensory perceptions as gauged by a human 
sensory test. A human sensory test directly gauges 
human sensory perceptions, so it offers the 
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advantage of providing direct information on a 
preparation, such as its taste and palatability
7-9
. 
Thus, information on a preparation, such as its taste 
and palatability, can presumably be gauged via a 
human sensory test in most instances. However, 
assessments of taste and palatability in a human 
sensory test are affected by participants‟ sex, age, 
and differences in taste due to diet, so uniform, 
objective assessment is difficult. An extremely 
interesting proposition would be to perform a 
human sensory test as well as to objectively assess 
the taste and palatability of preparations.  
 
Given a child‟s limited ability to swallow, children 
are often prescribed medication in forms that other 
patients with limited ability to swallow can take, 
such as powders, fine granules, granules, and dry 
syrups. The taste and palatability of preparations 
for children may affect patient compliance. 
However, preparation information such as the taste 
and palatability of fine granules for children is 
seldom provided in clinical practice. Previous 
studies of tulobuterol and teprenone by the current 
authors assessed and compared the taste of 
pharmaceutical preparations using a human sensory 
test and taste sensors. Results of those studies 
revealed a correlation between results of a human 
sensory test and readings from taste sensors, 
indicating the usefulness of human sensory testing 
and taste sensors. A correlation between results of 
human sensory testing and evaluation of the 
physicochemical properties of preparations might 
be identified in terms of the taste and palatability of 
preparations. Identification of this correlation 
would allow objective assessment in place of a 
human sensory test and provide a valuable source 
of information for clinical practice and 
development of preparations. 
  
Loperamide hydrochloride is widely used in 
clinical practice. Loperamide hydrochloride is an 
antidiarrheal that stimulates the μ- opioid receptors 
and inhibits gastrointestinal motility. Loperamide 
hydrochloride for use by children is sold in the 
form of fine granules and dry syrups. However, 
loperamide hydrochloride is a bitter drug. When 
given to children, children may refuse to take the 
drug because of the taste or palatability, i.e. 
bitterness, of a preparation. Thus, children have 
less compliance with taking their medication, 
reducing its efficacy.  
 
The current study used loperamide hydrochloride 
granules and dry syrup for children to examine the 
correlation between a human sensory test and the 
physicochemical properties of those preparations.  
The purpose of the present study was to evaluate 
taste by a human sensory test and the 
physicochemical properties of loperamide 
hydrochloride granules and dry syrup for children 
(Preparations A (brand medicine), B and C (generic 
medicines).Accordingly, between a human sensory 
test and the physicochemical properties of those 
preparations examine the correlation via 
measurement of particle size distribution, 
observation of particle morphology using scanning 
electron microscopy (SEM), measurement of sugar 
content analysis, and a dissolution test. 
 
MATERIALS AND METHODS 
 
Materials: Three different loperamide 
hydrochloride preparations for children were used 
in the present study: loperamide hydrochloride in 
its original form, Lopemin
®
 Fine Granules for 
Children 0.05% (Lot NO. 026AAG, 032BBJ, 
Janssen Pharmaceutical K.K., Preparation A), and 
in two generic forms, Taiyo
®
 0.05% Loperamide 
HCL (Lot NO. AX1423, BH1193, Teva Pharma 
Japan Inc., Preparation B) and Lopecald
®
 Dry 
Syrup 0.05% (Lot NO. AS01, Shiono Chemical 
Co., Ltd., Preparation C) (Table 1). Loperamide 
hydrochloride powder (Lot no. 23922603) from 
Wako Pure Chemical Industries, Ltd. was used. All 
other reagents were of special reagent grade.  
 
Human gustatory sensation tests:  Human 
gustatory sensation tests were performed with 41 
healthy human volunteers (18 males, 23 females, 
mean age: 22.7±3.5 years). This study was fully 
explained to potential volunteers and then their 
consent was obtained. Volunteers were given 0.2 g 
of each preparation in random order and asked to 
place it in their mouths. Volunteers then evaluated 
the preparation after it remained in their mouths for 
15 s. After each evaluation, volunteers immediately 
spit out the preparation and gargled with 25 mL of 
water. Each subject then evaluated the next 
preparation 15 min later to keep their evaluation 
from being influenced by the previous preparation. 
Evaluation was performed using a structured rating 
scale. Volunteers evaluated gustatory sensation 
using6 items: "bitterness," "sweetness," 
"solubility," "roughness," "palatability," and 
"overall impression" (Scheme1).This experimental 
protocol was approved by the Ethics Committee of 
Josai University.  
 
Measurement of the intensity of bitterness: The 
intensity of bitterness was measured in accordance 
with Katsuragi‟s method10-11. The standard for 
bitterness was quinine hydrochloride at 
concentrations of 0.01, 0.3, 0.10, 0.30, and 1.0 mM 
according to 46 healthy human volunteers (21 
males, 25 females, mean age: 22.6±1.2 years). Two 
mL of a solution with a varying concentration of 
quinine hydrochloride was kept in the mouth for 5 
s. After tasting, volunteers scored increasing 
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concentrations of the standard solution with scores 
of 0,1, 2, 3, and 4. Volunteers evaluated the 
bitterness of each preparation after it remained in 
their mouths for 15 s. After each evaluation, 
volunteers immediately spit out the preparation and 
gargled with 25 mL of water. Each subject then 
evaluated the next preparation 15 min later to keep 
their evaluation from being influenced by the 
previous preparation. This experimental protocol 
was approved by the Ethics Committee of Josai 
University. 
 
Sugar content according to a refractometer: 
The sugar content of each preparation was 
determined with an Atago Master-N1 sugar 
refractometer (Atago Co., Ltd., Japan) using 
concentrations of 2, 10, and 20 µg/mL. 
 
Measurement of particle size distribution: The 
particle size distribution in each preparation was 
measured using a dynamic light-scattering 
instrument (Malvern Mastersizer Scirocco 2000, 
Malvern Instruments Ltd., Worcs, U.K.). The 
particle size distribution was characterized using 
the mass median diameter d (0.5).  
 
Observation of particle morphology using SEM: 
A scanning electron microscope (Hitachi, 
modelS3000N, Japan) was used to observe the 
surface and shape of the particles in each 
preparation. SEM was performed with a metal 
coating and a voltage of 15 kV. 
 
Evaluation using a dissolution test: The content 
of loperamide hydrochloride in each preparation 
was weighed to the mg. A dissolution test was 
performed using the paddle method of dissolution 
behavior as specified in the 16th edition of the 
Japanese Pharmacopoeia. The dissolution medium 
was distilled water and a phosphate buffer, pH 6.8 
(900 mL, 37±0.5ºC). The rate of agitation of the 
paddle was 50 rpm. Standard dissolution was 
performed more than 85% in 15 minutes of 
loperamide hydrochloride granules in accordance 
with guidelines on generic. A phosphate buffer, pH 
6.8, was used to simulate dissolution of loperamide 
chloride from the preparation in the mouth. 
Samples (10 mL) were withdrawn at various time 
intervals using a syringe and filtered through a 
0.45µm membrane filter. The filtered loperamide 
solutions were used as the mobile-phase solution in 
HPLC.The drug concentrations in the solution were 
determined using HPLC (e2695, Waters Co., 
Japan), and an Inertsil
®
 ODS-3 column (4.6 
mm×150 mm, φ5 μm: GL Science, Inc. Japan) was 
used. The flow rate was adjusted to about 6 
minutes to serve as the retention time for 
loperamide hydrochloride. The column temperature 
was set at 40ºC, and the injection volume was 100 
μL. Loperamide hydrochloride dissolution was 
determined using a mobile phase of 
phosphate/triethylamine hydrochloride/acetonitrile 
(1/45/54, v/v/v). The measurement wavelength for 
loperamide hydrochloride dissolution was 214 nm. 
Statistical Analysis: Results are presented as 
mean±standard deviation, and statistical 
significance was evaluated using the Tukey Kramer 
Test. 
 
RESULTS 
 
Human gustatory sensation tests:  Human 
sensory test results for Preparations A, B, and C are 
shown in Fig. 1. In the human sensory test, 
significant differences in the attributes 
“bitterness,”“roughness,”“palatability” and “overall 
impression” were noted. Significant differences in 
the attribute “sweetness” were not noted. 
Preparation C scored highest for the attribute 
“bitterness”(bitterness score: 6.7), and significant 
differences between that score and scores for 
Preparations A and B were noted (p<0.001). 
Preparation B scored highest for the attribute 
“roughness”(roughness score: 5.8), and significant 
differences between that score and scores for 
Preparations B and A were noted (p<0.05). 
Significant differences between the scores for 
Preparations B and C were not noted. Preparation 
A scored highest for the attribute “solubility” 
(solubility score: 7.1), and significant differences 
between that score and scores for Preparations A 
and C were noted (p<0.05).Significant differences 
between the scores for Preparations A and B were 
not noted. Preparation A scored the highest for the 
attribute “palatability” (palatability score: 3.3), and 
significant differences between that score and 
scores for Preparations A and C were noted 
(p<0.001). Preparation A scored highest for the 
attribute “overall impression”(overall impression 
score: 4.8), followed by Preparation B (overall 
impression score: 3.9) and then Preparation C 
(overall impression score: 2.1). Preparation Chad 
the lowest overall impression score. Significant 
differences between that score and scores for 
Preparation A (p<0.001) and Preparation B(p<0.01) 
were noted.  
 
Measurements of the intensity of the bitterness of 
Preparations A, B, and C are indicated. Preparation 
Chad the most intense bitterness (bitterness score: 
3.20) while Preparations A and B had equivalent 
bitterness scores (about 1.6). Significant 
differences in the score for Preparation C and 
scores for Preparations A and B were noted 
(p<0.001). Significant differences in the scores for 
Preparations A and B were not noted. 
 
Yutaka Inoue et al., World J Pharm Sci 2015; 3(3): 570-579 
573 
 
The sugar content in each preparation was 
determined using concentrations of 2, 10, and 20 
µg/mL. The sugar content in each preparation at a 
concentration of 2 µg/mL was about 0.1% for 
Preparation A and about 0.3% for Preparations B 
and C. The sugar content in each preparation at a 
concentration of 10 µg/mL was about 1.7% for 
Preparations A, B, and C. The sugar content in 
each preparation at a concentration of 20 µg/mL 
was about 3.6% for Preparations A, B, and C. The 
sugar content in the preparations at all three 
concentrations (2, 10 and 20 µg/mL) was 
equivalent.  
 
The particle size distribution for Preparations A, B, 
and C is indicated. The median diameter of 
particles in each preparation of loperamide 
hydrochloride was 165.6 µm for Preparation A, 
188.7 µm for Preparation B, and 53.0 µm for 
Preparation C. Preparation A had particles that 
were mostly 200 µm in size, Preparation B had 
particles that were mostly 224 µm in size, and 
Preparation C had particles that were mostly 56 
µmin size. In addition, Preparation C was found to 
have a wide range of particle sizes ranging from 
small to large.  
 
The particle morphology in each sample was 
observed using SEM. The particle morphology in 
each preparation was found to differ. Preparations 
A and B mostly had particles of about 200 µm 
while Preparation C mostly had particles of about 
50 µm. In addition, particles in Preparations A and 
C were found to have a smooth surface. Particles in 
Preparation B were found to have a rough surface.  
A dissolution test of each preparation was 
performed in distilled water and in a phosphate 
buffer, pH6.8. The test indicated that the 
dissolution behavior of the3preparationsdiffered. In 
the dissolution test with distilled water, Preparation 
Chad the briefest period prior to dissolution, 
followed by Preparation A and then Preparation B. 
In the dissolution test with a phosphate buffer, pH 
6.8,to simulate conditions inside the mouth, results 
mirrored the test with distilled water. In other 
words, Preparation Chad the briefest period prior to 
dissolution, followed by Preparation A and then 
Preparation B. Preparation C had similar 
dissolution behavior in both test solutions 
dissolution behavior, and Preparation C had a 
briefer period prior to dissolution than the other 
preparations.  
 
DISCUSSION 
 
This study compared the taste and palatability of 
brand-name drugs and generics by performing a 
human sensory test and evaluating the 
physicochemical properties of loperamide 
hydrochloride preparations for children. 
Observations of particle morphology using SEM 
and measurements of particle size distribution 
(Figs. 3 and 4) indicated that Preparation B had a 
larger particle size and rougher particle surface. 
Thus, these properties may have led to its increased 
score for the attribute “roughness” in the human 
sensory test (Fig. 1). Particles in Preparations A 
and C had a smooth surface, which is presumably 
why they had lower scores for roughness than 
Preparation B. The roughness of a preparation in 
the mouth results in poor palatability and is 
reported to be a factor for noncompliance
12
. 
Preparation B had a significantly higher score 
forroughness than the other preparations, which is 
presumably the reason for its poor palatability and 
low overall impression. A dissolution test was 
performed in distilled water and in a solvent 
(phosphate buffer, pH 6.8) simulating the inside of 
the mouth (Figs. 5 and 6). Results of that test 
indicated that Preparation A had a slower period 
prior to dissolution in the phosphate buffer, pH 6.8, 
in comparison to its dissolution behavior in 
distilled water. However, differences in the 
dissolution behavior of the other 2 preparations in 
distilled water and in the phosphate buffer, pH 6.8, 
were not noted. In comparison to the other 2 
preparations addition, Preparation C had the 
briefest period prior to dissolution of the principal 
agent. A preparation‟s dissolution rate is an 
important aspect to consider in clinical practice. 
Several brand-name and generic preparations are 
reported to have different dissolution rates
13, 14
. A 
large contact surface area between a sample and a 
solvent typically results in a better dissolution 
rate
15, 16
. Observations of particle morphology 
using SEM and measurements of particle size 
distribution (Figs. 3, 4) revealed that Preparation C 
had a D50 of 53 µm, which means it had a smaller 
particle size than the other 2 preparations. The 
larger specific surface area and larger contact 
surface between the solvent and preparation 
particles may have led to the brief period prior to 
dissolution. Preparations A and B had a large D50, 
and this may be why they had a longer period prior 
to dissolution. Preparation C had the lowest score 
for the attribute “solubility” (Fig. 1) in the human 
sensory test. Preparation C is a dry syrup 
containing particles with a wide range of sizes, so 
large particles only begin to dissolve in the mouth. 
This may be why the preparation had a low score 
for solubility in the human sensory test. The only 
additives that Preparation C contained were sucrose 
and aromatic agents, which contrasted with 
Preparations A and B. Preparation C lacks a binder 
like that found in Preparations A and B 
(hydroxypropyl cellulose), so fine particles are not 
formed. Thus, Preparation C dissolved faster after a 
briefer period than the other preparations when 
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subjected to the paddle. Thus, the principal agent in 
Preparation C dissolves quickly under conditions 
like those inside the mouth. Faster dissolution of 
loperamide may account for the bitterness of that 
preparation. This is presumably why Preparation C 
had the highest score for the attribute “bitterness” 
in the human sensory test. Significant differences 
in the attribute “sweetness” (Fig. 1) of 
the3preparationsin the human sensory test were not 
noted. Measurements of sugar content (Table 2) 
also indicated that the preparations had almost the 
same sugar content. The sweetening agent 
contained in a preparation is reported to help mask 
bitterness. How effectively bitterness is masked 
may differ depending on the type of sweetening 
agentadded
17, 18
. Preparations A, B, and C all had 
sucrose as a sweetening agent (an excipient). 
Addition of sucrose as a sweetening agent 
presumably led to the lack of difference in how 
effectively bitterness was inhibited. However, 
Preparation C had a significantly higher score for 
the attribute “bitterness” (Fig. 1) in the human 
sensory test and more intense bitterness (Fig. 2) 
than the other preparations. The taste of a 
preparation is reported to change as a result of 
dissolution of bitter ingredients in the preparation 
and the sweetness, flavor, and aroma of additives
17-
20
. Adding a sour aromatic agent and sourness to a 
bitter preparation is reported to reduce the 
preparation‟s bitterness and increase its 
palatability
21
. Thus, a citrus aroma had been added 
to Preparation A, adding sourness to the principal 
agent and lessening bitterness. Preparation B 
included sodium citrate, which may have directly 
led to the sourness of the preparation and its 
reduced bitterness. In contrast, Preparation C had 
only sucrose and aromatic agents to mask 
bitterness, making it much less effective at masking 
bitterness than the other preparations. This may be 
which its bitterness was most apparent. Thus, 
Preparation C had significantly more intense 
bitterness than the other 2 preparations, resulting in 
its poor palatability and low overall impression 
score in the human sensory test. Of the 
preparations, Preparation C had the poorest 
palatability and lowest overall impression score.  
 
CONCLUSION 
  
A human sensory test was performed and the 
physicochemical properties of loperamide 
hydrochloride preparations for children were 
evaluated. Among the attributes assessed in the 
human sensory test, “sweetness,”“roughness,”and 
“solubility” were found to be correlated with 
assessed physicochemical properties. In addition, 
the attribute “bitterness” in the human sensory test 
was found to be correlated with measurement of 
the intensity of bitterness using quinine 
hydrochloride. Masked bitterness and improved 
palatability are major factors that affect the 
treatment of children and patient compliance. 
Ascertaining information on a preparation‟s 
properties can provide valuable information to 
improve patient compliance with medication, assist 
medical personnel, and help with development of 
preparations. This information can help with a wide 
range of treatments tailored to those requirements 
in clinical settings. In order to give pharmaceuticals 
appropriately, pharmacists must pay close attention 
to principal agents and additives as well as the 
characteristics of preparations and dispense those 
preparations accordingly.  
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Table 1: Additives of each formulation 
Formulation  Product name  Additives  
A  LOPEMIN
®
 Fine Granules  
for Children 0.05%  
Sucrose, Magnesium aluminometasilicate,  
Light anhydrous silicic acid, Magnesium stearate,  
Hydroxypropyl cellulose (HPC), Carmellose calcium,  
Sunset yellow FCF, Flavour  
B  LOPERAMIDE HCL
®
  
0.05%「TAIYO」  
Sucrose, Corn starch, Hydrated silicon dioxide, HPC,  
Carmellose calcium, Sodium citrate hydrate,  
Propylene glycol, sunset yellow FCF, Flavour  
C  LOPECALD
®
 DS 0.05%  White soft sugar, Flavour  
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Table 2:. Brix measurement of each formulation  
Formulation  
Concentration of Loperamide  (µg/mL)  
 
2  
  
10  
  
20  
 
A  0.11  ±  0.01%  1.69  ±  0.03%  3.68  ±  0.03%  
B  0.30  ±  0.04%  1.70  ±  0.03%  3.61  ±  0.03%  
C  0.37  ±  0.03%  1.70  ±  0.03%  3.60  ±  0.04%  
n=4 mean±S.D 
 
Scheme 1: List of aspect evaluated by human gustatory sensation test 
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Figure 1: Result of human sensory test*p<0.05, ***p<0.001  (Tukey Kramer Test, n=40, mean±S.D.).  
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Figure 2: Bitterness intensity measurements for each formulation ***p< 0.001 (Tukey Kramer Test, n=46 
mean± S.D.).  
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Figure 3: Particle size distribution for each formulation a) Formulation A, b) Formulation B, c) Formulation C 
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Figure 4: Scanning electron microscopy photograph of each formulation. 
a-1) Formulation A (×60), b-1) Formulation B (×60), c-1) Formulation C (×95),  
a-2) Formulation A (×80), b-2) Formulation B (×210), c-2) Formulation C (×650).  
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Figure 5: Dissolution test of each formulation using water (n =3).  
 
 
 
 
Figure 6: Dissolution test of each formulation using phosphoric buffer pH 6.8 (n =3). 
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